Valer L - Search Results

1

Failure to detect human immunodeficiency virus type 1 superinfection in 28 HIV-seroconcordant individuals with high risk of reexposure to the virus.

Chakraborty B, Valer L, De Mendoza C, Soriano V, Quiñones-Mateu ME. Chakraborty B, et al. Among authors: valer l. AIDS Res Hum Retroviruses. 2004 Sep;20(9):1026-31. doi: 10.1089/aid.2004.20.1026. AIDS Res Hum Retroviruses. 2004. PMID: 15585092

2

[HIV superinfection: clinical and biological implications].

Valer L, de Mendoza C, Soriano V. Valer L, et al. Med Clin (Barc). 2003 Jul 5;121(5):192-6. doi: 10.1016/s0025-7753(03)73899-8. Med Clin (Barc). 2003. PMID: 12867008 Review. Spanish.

3

Predictors of selection of K65R: tenofovir use and lack of thymidine analogue mutations.

Valer L, Martín-Carbonero L, de Mendoza C, Corral A, Soriano V. Valer L, et al. AIDS. 2004 Oct 21;18(15):2094-6. doi: 10.1097/00002030-200410210-00018. AIDS. 2004. PMID: 15577635

4

Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir/ritonavir.

Valer L, De Mendoza C, De Requena DG, Labarga P, García-Henarejos A, Barreiro P, Guerrero F, Vergara A, Soriano V; Fortogene Spanish Study Group. Valer L, et al. AIDS. 2002 Sep 27;16(14):1964-6. doi: 10.1097/00002030-200209270-00016. AIDS. 2002. PMID: 12351959 No abstract available.

5

Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients.

Valer L, de Mendoza C, Soriano V. Valer L, et al. J Med Virol. 2005 Dec;77(4):460-4. doi: 10.1002/jmv.20477. J Med Virol. 2005. PMID: 16254964

6

Resistance mutations in HIV-infected patients experiencing early failure with nelfinavir-containing triple combinations.

Núńez M, de Mendoza C, Valer L, Casas E, López-Calvo S, Castro A, Rosón B, Podzamczer D, Rubio A, Berenguer J, Soriano V. Núńez M, et al. Among authors: valer l. Med Sci Monit. 2002 Sep;8(9):CR620-3. Med Sci Monit. 2002. PMID: 12218942

7

Impact of drug levels and baseline genotype and phenotype on the virologic response to amprenavir/ritonavir-based salvage regimens.

Valer L, González de Requena D, de Mendoza C, Martin-Carbonero L, González-Lahoz J, Soriano V. Valer L, et al. AIDS Patient Care STDS. 2004 Jan;18(1):1-6. doi: 10.1089/108729104322740857. AIDS Patient Care STDS. 2004. PMID: 15006188 Clinical Trial.

8

Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients.

Marcelin AG, Flandre P, de Mendoza C, Roquebert B, Peytavin G, Valer L, Wirden M, Abbas S, Katlama C, Soriano V, Calvez V. Marcelin AG, et al. Among authors: valer l. Antivir Ther. 2007;12(2):247-52. Antivir Ther. 2007. PMID: 17503666

9

Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors.

Barreiro P, Camino N, de Mendoza C, Valer L, Núñez M, Martín-Carbonero L, González-Lahoz J, Soriano V. Barreiro P, et al. Among authors: valer l. Int J Antimicrob Agents. 2002 Dec;20(6):438-43. doi: 10.1016/s0924-8579(02)00250-9. Int J Antimicrob Agents. 2002. PMID: 12458138 Clinical Trial.

10

Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance.

de Mendoza C, Valer L, Bacheler L, Pattery T, Corral A, Soriano V. de Mendoza C, et al. Among authors: valer l. AIDS. 2006 Apr 24;20(7):1071-4. doi: 10.1097/01.aids.0000222084.44411.cc. AIDS. 2006. PMID: 16603864

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

20 results

Search Page

Filters